Teva, Intel to develop wearable machine-learning tech for Huntington’s

Teva and Intel are joining forces on a wearable device and machine-learning platform to improve the understanding and treatment of Huntington’s disease. The duo plans to deploy the platform, which will enable continuous monitoring and analysis of Huntington’s symptoms, in a substudy in an ongoing Phase II trial of the drug pridopidine in people with Huntington’s, according to a statement. They hope to launch the study in the U.S. and Canada by the end of the year. The platform comprises a smartphone and smartwatch that will measure patients’ “general functioning and movement,” the companies said in a statement. The data will then be wirelessly transmitted to a cloud-based platform developed by Intel, where it will be analyzed and translated by algorithms into quantifiable scores for motor symptom severity, according to…


Link to Full Article: Teva, Intel to develop wearable machine-learning tech for Huntington’s